We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
OPDIVO Bristol-Myers Squibb Australia Pty Ltd
Product name
OPDIVO
Accepted date
Jan-2026
Active ingredients
nivolumab
Summary of proposed indication
OPDIVO (nivolumab) is proposed to be used together with the chemotherapy medicines doxorubicin, vinblastine, and dacarbazine to treat adults and teenagers aged 12 and over who have advanced classical Hodgkin lymphoma (Stage III or IV) and who have not received prior treatment.
Application type
C (new indication)
Publication date
Jan-2026